A company with leading share in almost every relevant segment of a $24
billion market, strong margins, and strong barriers to entry arguably
should trade at healthy multiples, so I can't say that the valuation of Zoetis (NYSE:ZTS)
comes as much of a surprise. What's more, the company isn't done
growing and expanding, as the company can still target share growth in
Europe, market growth in emerging markets like China, margin
improvement, and expansion into adjacent markets/products. Even so, the
valuation gives me pause, as I believe it already factors in strong
growth and over $2.1 billion in free cash flow in 2026.
Continue here:
Zoetis: A Well-Loved Leader
Showing posts with label Zoetis. Show all posts
Showing posts with label Zoetis. Show all posts
Thursday, March 16, 2017
Monday, June 2, 2014
The Motley Fool: 3 Reasons to Like Zoetis
Wall Street is often willing to pay extra to sleep better at night, and Zoetis (NYSE: ZTS )
is the sort of business that won't often lead investors to lose much
sleep. The largest player in animal health, Zoetis is in the top three
in every relevant sub-market it addresses and is often #1 or #2, but its
leading product is less than 10% of sales and the top 10 list of
products is less than 40% of revenue. Helping Zoetis' valuation even
further is the relative lack of alternatives – companies like Neogen, Virbac, and Dechra
are much, much smaller (and harder to own for larger funds), while the
big comparables remain locked within large pharmaceutical companies like
Merck (NYSE: MRK ) , Sanofi (NYSE: SNY ) , and Lilly (NYSE: LLY ) .
Read more here:
3 Reasons to Like Zoetis
Read more here:
3 Reasons to Like Zoetis
Tuesday, September 24, 2013
The Motley Fool: Will 3 Versions Of Pfizer Be More Valuable Than 1?
Like many value-oriented investors, I tend to take a dim view of
companies that resort to financial gymnastics to make their reported
numbers look better or to get a better valuation from investors. With
that said, I'm curious, and more than a little skeptical, as to whether Pfizer's (NYSE: PFE )
long-term plan to potentially break itself up into three separate
companies will really generate any long-term value for investors.
To be fair, Pfizer has already done a little bit of this already. The company spun off Zoetis -- the world's largest animal health company with almost 20% share -- earlier this year, and Pfizer's shares have outperformed the S&P 500 by about 5% since then while Zoetis has lagged (though Zoetis is up more than 20% if you take the IPO price as the starting point). Time will tell regarding the ultimate value created by this transaction, but freeing Zoetis to invest in R&D and market development as it sees fit ought to be a win-win for both parties.
Please click here to continue:
http://www.fool.com/investing/general/2013/09/24/will-three-versions-of-pfizer-be-more-valuable-tha.aspx
To be fair, Pfizer has already done a little bit of this already. The company spun off Zoetis -- the world's largest animal health company with almost 20% share -- earlier this year, and Pfizer's shares have outperformed the S&P 500 by about 5% since then while Zoetis has lagged (though Zoetis is up more than 20% if you take the IPO price as the starting point). Time will tell regarding the ultimate value created by this transaction, but freeing Zoetis to invest in R&D and market development as it sees fit ought to be a win-win for both parties.
Please click here to continue:
http://www.fool.com/investing/general/2013/09/24/will-three-versions-of-pfizer-be-more-valuable-tha.aspx
Labels:
Abbott Labs,
AbbVie,
Pfizer,
The Motley Fool,
Zoetis
Subscribe to:
Posts (Atom)